Genmab AS
$ 26.43
-2.33%
08 May - close price
- Market Cap 16,225,657,000 USD
- Current Price $ 26.43
- High / Low $ 26.76 / 25.34
- Stock P/E 20.02
- Book Value 9.49
- EPS 1.32
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.08 %
- ROE 0.15 %
- 52 Week High 35.43
- 52 Week Low 18.89
About
Genmab A / S develops antibody therapies for the treatment of cancer and other diseases mainly in Denmark. The company is headquartered in Copenhagen, Denmark.
Analyst Target Price
$37.55
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-07 | 2026-02-17 | 2025-11-06 | 2025-08-07 | 2025-05-08 | 2025-02-12 | 2024-11-06 | 2024-08-08 | 2024-05-02 | 2024-02-14 | 2023-11-07 | 2023-08-03 |
| Reported EPS | 0.1335 | 0.21 | 0.65 | 0.54 | 0.31 | 0.84 | 0.29 | 0.32 | 0.29 | 0.14 | 0.46 | 0.3 |
| Estimated EPS | 0.18 | 0.37 | 0.45 | 0.34 | 0.2 | 0.28 | 0.33 | 0.32 | 0.14 | 0.3 | 0.31 | 0.29 |
| Surprise | -0.0465 | -0.16 | 0.2 | 0.2 | 0.11 | 0.56 | -0.04 | 0 | 0.15 | -0.16 | 0.15 | 0.01 |
| Surprise Percentage | -25.8333% | -43.2432% | 44.4444% | 58.8235% | 55% | 200% | -12.1212% | 0% | 107.1429% | -53.3333% | 48.3871% | 3.4483% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: GMAB
2026-05-09 00:09:17
Genmab (CPSE:GMAB) reported Q1 2026 revenue of US$896 million and basic EPS of US$0.84, with trailing 12-month net margins compressing to 21% from 35.3% a year prior. This margin compression, coupled with volatile quarterly net income and concerns about debt coverage by operating cash flow, presents a challenge to the company's long-term growth narrative despite analysts forecasting 18% annual earnings growth. The stock's current P/E of 19.3x is above peers, yet it trades significantly below its DCF fair value and analyst price targets, complicating the valuation picture for investors.
2026-05-08 22:40:12
Genmab announced that Orbis Investment Management Limited has become a major shareholder, acquiring a 5.08% voting stake amounting to 3,166,357 shares. This signals strong institutional interest in Genmab's antibody-driven oncology portfolio and growth prospects. While the current analyst rating for GMAB is a Hold with a $33.00 price target, TipRanks’ AI Analyst, Spark, rates it Neutral, citing strong financials but concerns about increased leverage and weaker earnings quality signals.
2026-05-08 20:40:12
Orbis Investment Management Limited has increased its voting rights in Genmab A/S (Nasdaq: GMAB) to 5.08%, crossing a significant disclosure threshold under Danish regulations. This change, reported in a Form 6-K SEC filing, means the Allan & Gill Gray Foundation group, which includes Orbis, now controls 3,166,357 Genmab shares, up from a previous 4.8471%. The foundation group's total voting rights are stated as 5.0783% of Genmab's share capital, and all holdings are through shares, with no exposure via financial instruments.
2026-05-08 19:40:12
Genmab A/S announced that Orbis Investment Management Limited holds a 5.08% stake in the company as of May 8, 2026. This information was published on May 8, 2026, at 3:10 pm EDT. The article also provides a company profile for Genmab, outlining its focus on research and development of therapeutic antibodies for various diseases, with primary revenue streams from royalties and product sales.
2026-05-08 19:09:17
Genmab A/S announced that Orbis Investment Management Limited holds a 5.08% stake in the company as of May 8, 2026. This information was reported via Reuters and Refinitiv. The article is very brief, providing a direct statement about the institutional ownership.
2026-05-08 18:40:12
Genmab A/S announced that Orbis Investment Management Limited has become a major shareholder. As of May 8, 2026, Orbis Investment Management Limited controls 3,166,357 shares, representing 5.08% of Genmab A/S's share capital and voting rights. This disclosure was made in accordance with Section 30 of the Danish Capital Markets Act.
